Theme Member
Dr David Yeung




BSc (Med) MBBS (Hons) UNSW, PhD (Adelaide), FRACP, FRCPA.

Research Focus

David Yeung is a postdoctoral research fellow with the Cancer Theme at the SHAMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases. David also has project with Prof Deb White of the Cancer Theme, who heads the national effort in understanding and improving outcomes in high risk ALL. He has co-authored 24 publications in peer reviewed journals and 2 book chapters in postgraduate text books.


Barratt DT, Cox HK, Yeung DT, White DL, Hughes TP, Somogyi AA. CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics. Accepted for publication 29 Nov 2016.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.179 [Epub ahead of print] PMID: 27416909

Nievergall E, Reynolds J, Kok CH, Watkins D, Biondo M, Busfield S, Vairo G, Fuller K, Erber W, Sandras T, Grose R, Yeung DT, Lopez A, Hiwase DK, Hughes TP, White DL. TGF- α and IL-6 plasma levels selectively identify CML patients that fail to achieve an early molecular response or progress in the first year of therapyLeukemia. 2016 Jun;30(6):1263-72. PMID: 26898188

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison B, Field CR, Hodgson JG, Lustgarten S, Rivers VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016 Apr 14;127(15):1870-80 PMID: 26773037

Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong AS. KIR2DL5B Genotype Predicts Outcomes in CML Patients Treated with Response Directed Sequential Imatinib / Nilotinib Strategy. Blood. 2015 Dec 17;126(25):2720-3. PMID: 26500342.

Ong J, Yeung D, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. Int J Hematol. 2015 Jul 2. DOI 10.1007/s12185-015-1824-y. PMID: 26134364.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP. TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015 Feb 5;125(6):915-23.PMID: 25519749

Yeung DT & Mauro MJ. Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program2014;2014:240-243. PMID: 25696861

Yeung DT, Moulton D, Heatley S et al. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment Leukemia. 2015 Jan;29(1):230-2. PMID: 25179732

Subramaniam K, Yeung D, Grimpen F, Joseph J, Fay K, Buckland M, Talaulikar D, Elijah J, Clarke AC, Pavli P, Moore J. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014 Mar;44(3):287-90. doi: 10.1111/imj.12363. PMID: 24621284

Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Parker Blood. 2014 Jul 3;124(1):153-5.PMID: 24993880

Branford S, Yeung DT, Parker WT et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood May 23, 2014. Blood. 2014 Jul 24;124(4):511-8. PMID: 24859364

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-22. PMID: 23704092

Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013 Sep 17;109(6):1593-8. PMID: 23799845

Branford S, Yeung DT, Ross DM et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19):3818-24. PMID: 23515925

Yeung DT, Branford, S. Monitoring disease response in Chronic Phase CML – the age of molecular assays? ASH evidence based mini review. Hematology Am Soc Hematol Educ Program. 2012;2012:111-4. PMID: 23233568

Van Dyke K, Fitter S, Drew J, Fukumoto TKY, Schultz C, Sims N, Yeung DT, Hughes TP & Zannettino A. Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab. 2013;98(1):67-76. PMID: 23144472

Branford S, Yeung DT, Prime J, Choi SY, Bang J, Park JE, Kim, D-W, Ross, DM, Hughes TP. BCR-ABL1 doubling-times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold-rise: implications for monitoring and management. Blood. 2012 May 3;119(18):4264-71. PMID: 22431575

Yeung DT, Hughes TP. Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia. Crit Rev Oncog. 2012;17(1):17-30. PMID: 22471662


2017 Editorial Board Member, Journal of the Asia-Pacific Bone Marrow Transplantation Group

2016 Centre for Cancer Biology Best postgraduate student publication

2016 Dean’s Commendation for Doctoral Thesis Excellence

2015 Session Chair, 2015 ASH annual scientific meeting CML oral abstracts session

2015 Abstract Achievement Award, American Society of Hematology Annual Meeting

2015 CML/MPN disease group co-chair, Australasian Leukaemia and Lymphoma Group

2013 PhD Scholarship, AR Clarkson, Royal Adelaide Hospital Research Foundation

2011 Scholar, American Society of Hematology Clinical Training Research Institute

Get in touch
+61 8 8128 4000
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.